Effect of Pioglitazone Therapy on Myocardial and Hepatic Steatosis in Insulin-Treated Patients with Type 2 Diabetes
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
High levels of myocardial and hepatic triglyceride are common in obesity and type 2 diabetes. Monotherapy with thiazolidinedione agents reduces hepatic steatosis by up to 50% in patients with type 2 diabetes. It is not known if treatment with a thiazolidinedione added to insulin has a similar beneficial antisteatotic effect. The aim of our study was to determine whether the addition of pioglitazone to insulin treatment in patients with type 2 diabetes has antisteatotic action in the heart and the liver. Thirty-two patients were randomized to 6 months of treatment with insulin or insulin plus pioglitazone. In addition to blood tests, we evaluated myocardial and hepatic triglyceride content, as well as subcutaneous and visceral fat mass at the L2 level, by magnetic resonance spectroscopy and imaging, respectively. Despite weight and subcutaneous fat mass gain, hemoglobin A 1c was significantly reduced by both treatments. Myocardial and hepatic triglyceride contents were reduced by the treatment with pioglitazone plus insulin ( p = .02 and .03, respectively) but not by the treatment with insulin. Systolic and diastolic blood pressure and heart function remained unchanged in both groups. The addition of pioglitazone to insulin therapy reduced myocardial and hepatic steatosis, consistent with the reported ability of the thiazolidinedione agents to redistribute fat from nonadipose to subcutaneous adipose depots.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“The most powerful way to correct energy imbalance and efficiently reverse the cytosolic fat accumulation is lifestyle adjustment intervention.(14,15) Unfortunately, the compliance with lifestyle strategies is difficult and frequently fails.”
BackgroundPrevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Self-citationYki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Lipotoxic heart disease in obese rats: Implications for human obesity
Zhou, Y.-T., Grayburn, P., Karim, A., Shimabukuro, M., Higa, M., Baetens, D., Orci, L., & Unger, R. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1784 · Cited by 1,265 · cited 1×
“Evidence from animal models suggests that accumulation of lipid in nonadipose tissues plays an important role in the pathogenesis of obesity, type 2 diabetes, steatohepatitis, and heart failure.(5,6) High serum TG levels and primary dyslipidemias are common in obesity(7,8) and in type 2 diabetes.”
BackgroundIntramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart
Sharma, S., Adrogue, J. V., Golfman, L., Uray, I., Lemm, J., Youker, K., Noon, G. P., Frazier, O. H., & Taegtmeyer, H. (2004) · The FASEB Journal · doi:10.1096/fj.04-2263com · Cited by 790 · cited 1×
“Evidence from animal models suggests that accumulation of lipid in nonadipose tissues plays an important role in the pathogenesis of obesity, type 2 diabetes, steatohepatitis, and heart failure.(5,6) High serum TG levels and primary dyslipidemias are common in obesity(7,8) and in type 2 diabetes.”
BackgroundRelationships of generalized and regional adiposity to insulin sensitivity in men.
Abate, N., Garg, A., Peshock, R. M., Stray-Gundersen, J., & Grundy, S. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118083 · Cited by 759 · cited 1×
“Abdominal Imaging Subcutaneous and visceral abdominal fat masses were determined from high-resolution abdominal axial images at the L2 level.(26) During data acquisition, patients were in the prone position.”
MethodMeasurement of intracellular triglyceride stores by H spectroscopy: validation in vivo
Szczepaniak, L. S., Babcock, E. E., Schick, F., Dobbins, R. L., Garg, A., Burns, D. K., McGarry, J. D., & Stein, D. T. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.5.e977 · Cited by 688 · cited 1×
“8 ppm.(3,7) The validation and reproducibility of the method measuring TG within the liver and the heart have been published.”
MethodSelf-citation
Cited by
Cusi, K. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 911
DeFronzo, R. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1684-1 · Cited by 879
Rijzewijk, L. J., van der Meer, R. W., Smit, J. W. A., Diamant, M., Bax, J. J., Hammer, S., Romijn, J. A., de Roos, A., & Lamb, H. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.062 · Cited by 559
“Furthermore, pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, which has the capacity to divert fat from nonadipose tissue to subcutaneous tissue, has been shown to lower myocardial triglyceride content in T2DM patients on an insulin-based treatment regimen (33).”
BackgroundPreiss, D., & Sattar, N. (2008) · Clinical Science · doi:10.1042/cs20070402 · Cited by 292
Myocardial, Perivascular, and Epicardial Fat
Iozzo, P. (2011) · Diabetes Care · doi:10.2337/dc11-s250 · Cited by 271
Role of Insulin Resistance and Lipotoxicity in Non-Alcoholic Steatohepatitis
Cusi, K. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.009 · Cited by 266
Ectopic lipids and organ function.
Szendroedi, J., & Roden, M. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328321b3a8 · Cited by 200
Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management
Pappachan, J. M., Varughese, G. I., Sriraman, R., & Arunagirinathan, G. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i5.177 · Cited by 190
Diabetic cardiomyopathy: where we are and where we are going
Lee, W.-S., & Kim, J. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.208 · Cited by 163
“Diabetes management was also beneficial for reducing myocardial steatosis [93].”
BackgroundGaborit, B., Kober, F., Jacquier, A., Moro, P. J., Cuisset, T., Boullu, S., Dadoun, F., Alessi, M.-C., Morange, P., Clément, K., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.117 · Cited by 116
Ectopic fat and insulin resistance
Lettner, A., & Roden, M. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0032-z · Cited by 106
Attaran, F., Emami, S., Sohrabi, M., Malek, M., Ajdarkosh, H., Khoonsari, M., Ismail-Beigi, F., & Khamseh, M. E. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02948-4 · Cited by 22
“In addition, piogl-itazone reduces both myocardial and hepatic triglyceride content [41] and inhibits the inflammatory process that is associated with myocardial fibrosis [40].”
Background
Metadata
- Authors
- Zib, I., Jacob, A. N., Lingvay, I., Salinas, K., McGavock, J. M., Raskin, P., & Szczepaniak, L. S.
- Venue
- Journal of Investigative Medicine
- Publisher
- SAGE Publications
- Published
- 2007-07
- Volume
- 55
- Issue
- 5
- Pages
- 230-236
- ISSN
- 1081-5589 (ISSN-L)
- 1708-8267
- OpenAlex
- W1971207050
- Cited by
- 79
- References
- 13
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.